Sanofi News

Sanofi | 6-K: Sanofi Q1 Robust 7% Sales Growth Driven by Launches, Underpins Full-Year Guidance

Apr 25 10:55 ET

Sanofi | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

Apr 4 14:11 ET

Sanofi | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Apr 4 08:50 ET

Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis

Mar 20 14:13 ET

Sanofi | S-8 POS: S-8 POS

Mar 15 08:45 ET

Sanofi | 6-K: Colletion of Recent Announcements

Feb 27 11:41 ET

Sanofi | IRANNOTICE: IRANNOTICE

Feb 23 14:05 ET

Sanofi | 20-F: Registration statement / Annual report / Transition report

Feb 23 11:20 ET

Sanofi | 6-K: Peer Support, Flexible Work Arrangements, Salary for a Year: Sanofi Launches Global Program for Employees Affected by Cancer and Critical Illnesses

Feb 15 12:12 ET

Sanofi | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

Feb 14 16:05 ET

Sanofi | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Dodge & Cox(4.9%)

Feb 13 14:00 ET

Sanofi | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.2%)

Feb 6 15:18 ET

Sanofi | 6-K: Dupixent® FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) and François-Xavier Roger Appointed Chief Financial Officer, Member of Sanofi Executive Committee

Feb 2 13:26 ET

Sanofi | 6-K: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

Feb 1 09:46 ET

Sanofi | 6-K: Sanofi to Acquire Inhibrx, Inc., Adding Potential Best-in-Class Rare Disease Asset for Alpha-1 Antitrypsin Deficiency to Pipeline

Jan 23 00:00 ET

Sanofi | 6-K: Brian Foard Appointed Head of Specialty Care Global Business Unit, Member of Sanofi Executive Committee

Jan 17 00:00 ET

Sanofi | 6-K: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint

Dec 27, 2023 00:00 ET

Sanofi | 6-K: Colletion of Recent Announcements

Dec 20, 2023 10:39 ET

Sanofi | F-6EF: Auto effective registration statement for American Depositary Receipts representing securities of certain foreign private issuers

Dec 18, 2023 17:23 ET

Sanofi | 6-K: Dupixent® Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

Dec 1, 2023 12:19 ET